Navigation Links
POZEN Announces Positive Outcome for PA 325 Proof of Concept Study

Food and Drug Administration, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for conditions such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: POZEN Announces Positive Outcome for Proof Concept Study
(Date:7/28/2015)... -- A German Diabetes Center clinical study found that ... enriches human gut microbiota and modifies gut production of ... daily administration of Nutraceutix,s L. reuteri strain ... tract ® delivery technology that protects live ... to the intestinal tract. The randomized, double-blind, ...
(Date:7/28/2015)... The Physician-Patient Alliance for Health & Safety ... Surviving Your Hospital Stay ." "Help us ... of these patients went home from hospital," said ... referring to the patient stories presented at ... Promote Continuous Monitoring of Patients on Opioids (shown ...
(Date:7/28/2015)... TAMPA, Fla. , July 28, 2015  For ... by their researchers, physicians and other inventors can be ... to market is difficult, and successes are rare. ... wants to change that. Medical Device ... technology licensed from universities, hospitals and physicians. MDI develops, ...
Breaking Medicine Technology:Nutraceutix's L. reuteri Probiotic Clinically Proven to Modulate Gut Insulin Metabolism 2Surviving Your Hospital Stay: Physician-Patient Alliance for Health & Safety Launches Fundraising for Patient Safety 2Medical Device Investments To Become Center Of Excellence For The Commercialization Of Innovative Medical Technologies 2
... Significance, FRAZER, Pa., May 01, 2007 /PRNewswire-FirstCall/ ... presented today at the 59th Annual,Meeting of ... highlights,data demonstrating that FENTORA(R) (fentanyl buccal tablet) ... pain in patients,with neuropathic pain who are ...
... Inc. (NYSE:DNA),and Biogen Idec, Inc. (Nasdaq:BIIB) announced ... study of Rituxan(R) (rituximab) in,patients with relapsing-remitting ... American Academy of Neurology annual meeting,held in ... targets and,selectively depletes CD20-positive B-cells., "There remains ...
Cached Medicine Technology:Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 2Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 3Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 4Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 5Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 6Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 7Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6
(Date:7/28/2015)... ... , ... Talking About Your Product Pipeline:, How FDA and SEC Regulate Life ... http://www.fdanews.com/productpipeline , When a company has a product in development, whether drug, ... tightly regulated by the FDA. , At the same time, the SEC requires that ...
(Date:7/28/2015)... West Jordan, Utah (PRWEB) , ... July 28, ... ... Medical Center West Valley Campus have received the Get With The Guidelines®-Stroke Gold ... Association for excellence in patient care and outcomes. , The Get With ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... products, announces Skimmer Helper, a household invention that cleans pools efficiently - minus ... billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing. "It ...
(Date:7/28/2015)... ... July 28, 2015 , ... World ... Lost and Found, a breakthrough technological invention. It is a wearable personal ... consumer electronic industry reached a record high of $211.3 billion in 2014," says ...
(Date:7/28/2015)... ... ... Dr. Edward Buckingham and Buckingham Center for Facial Plastic Surgery, is ... to Austin from Philadelphia, Dr. Roy will be completing his Fellowship in facial plastic ... by the American Academy of Facial Plastic and Reconstructive Surgery. , Since 1969, ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Talking About Your Product Pipeline: How FDA and SEC Regulate Life Sciences Communications Webinar, Aug. 19, 2015 2Health News:FDAnews Announces — Talking About Your Product Pipeline: How FDA and SEC Regulate Life Sciences Communications Webinar, Aug. 19, 2015 3Health News:FDAnews Announces — Talking About Your Product Pipeline: How FDA and SEC Regulate Life Sciences Communications Webinar, Aug. 19, 2015 4Health News:Jordan Valley Medical Center and Jordan Valley Medical Center West Valley Campus Receive Stroke Award 2Health News:Jordan Valley Medical Center and Jordan Valley Medical Center West Valley Campus Receive Stroke Award 3Health News:10 Fascinating Things You Never Knew About Swimming Pools Is Introduced by World Patent Marketing and Skimmer Helper 2Health News:10 Fascinating Things You Never Knew About Swimming Pools Is Introduced by World Patent Marketing and Skimmer Helper 3Health News:10 Fascinating Things You Never Knew About Swimming Pools Is Introduced by World Patent Marketing and Skimmer Helper 4Health News:10 Fascinating Things You Never Knew About Swimming Pools Is Introduced by World Patent Marketing and Skimmer Helper 5Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 2Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 3Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 4Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 5Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 2Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 3
... were more likely to report a family history of ... who did not have prostate// cancer, according to researchers ... ,The data were part of the Flint Men’s Health ... who live in Flint, Mich. The Flint Men's Health ...
... is not well and cannot attend court the next three ... ago following chest pain. ,"He is not well. I ... court proceedings for the next three days," said Shakti Gupta, ... Sciences (AIIMS). ,According to Gupta, six heart ...
... boost its health tourism industry in the US, says an ... of Kerala Associations in North America (Fokana), which has members ... Kerala governments to promote the state as a destination for ... attention of the entire US. If Kerala does it, there ...
... Tuberculosis, a highly communicable disease, has turned out to be ... affected nations in the world. It is estimated //that nearly ... ,This has raised the concern of Kenyan doctors and ... label tuberculosis as a national debacle and formulate special laws ...
... to see that a robust and effective legislation which ... life is brought into force within the next six ... AIDS Day organized by Parliamentarians Forum on HIV/AIDS and ... following suggestions to MPs, research laboratories, the Pharma industry ...
... the Western Pacific region to take action to curb HIV. ... in Aids infection with figures escalating to 8.6 million. Only ... year. WHO has issued the call to governments to intervene ... virus. ,Mr. Shigeru Omi, the director for ...
Cached Medicine News:Health News:African-Americans With Prostate Cancer More Likely to Have Family History 2Health News:President Urges to Avoid Discrimination Against AIDS Patients 2
Galt Skull Trephine with adjustable centering point and detachable cross-bar handle, 19.0 mm....
Greenberg micro instrument holder is a flexbar arm used to hold micro instruments used repeatedly within retracted fields. Holds instruments with shafts up to 1/8 in diameter....
Length-9 (229 mm) Tapered retractor blades. 1/16 x 1/4 (1.6 mm x 19 mm)....
Kit is supplied with four secondary bars. Secondary bars attach to primary bar. Length 12 (305 mm)....
Medicine Products: